What is the A4 Study?
The A4 Study (also known as the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study) is a landmark clinical trial to prevent the memory loss associated with Alzheimer’s disease (AD). The A4 study is for individuals ages 65 to 85 who may be at risk for AD-related memory loss but who have no outward signs of the disease.
The A4 study is investigating a new treatment that may reduce the impact of a protein known as “amyloid” or “beta amyloid” which forms plaques in the brain. Scientists believe that the accumulation of amyloid in the brain may play a key role in the eventual development of AD-related memory loss.
The investigational treatment used in A4 targets the excess amyloidin the brain with the aim of slowing possible AD-related damage in the brain and delaying symptoms of memory loss
You may be eligible to participate in the A4 study if you:
·Are 65 to 85 years old ·Have normal thinking and memory abilities ·Have an A4 study partner who has at least weekly contact with you and can answer questions once a year ·Are willing and able to receive intravenous infusions (IV) of the investigational treatment or placebo (monthly infusions).
What is involved in the A4 study?
The study lasts approximately three years and participants will be required to visit the clinical research site once a month. Participants will have their health monitored throughout the study using assessments such as:
·Memory and thinking tests ·ECGs ·PET scan ·MRI scans ·Blood and urine tests
A4 participants must be willing and able to participate in all required procedures for the duration of the A4 study.